Developer docs
API playgroundTry for free, no card

Search company profiles

Apricot Capital

Full company profile

uuid0000pcd

Namestring
Apricot Capital
Legal namestring
Apricot Capital CJSC
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Apricot Capital is a Shanghai-based venture capital investment firm founded in 2015 that focuses on early and growth-stage companies in the healthcare and life sciences sectors. The firm operates with a team of 11-50 employees and pursues a cross-border investment strategy, co-investing alongside prominent institutional investors including Pfizer Ventures, Qiming Venture Partners, HSG, Yuanbio Venture Capital, Highlight Capital, TF Capital, and Loyal Valley Capital. Its portfolio is anchored by clinical-stage and early-clinical biotechnology companies developing T-cell engager therapies and RNA-targeting therapeutics, including Vibrant Therapeutics (T-cell engagers for solid tumors, $100M total raised), Excalipoint Therapeutics (T-cell engagers for cancer and autoimmune diseases, $68.7M seed), and Vivatides Therapeutics (extrahepatic RNA-targeting therapeutics, $54M Series A).

The firm's business model is capital deployment into portfolio companies rather than product sales, with revenue derived from conventional VC mechanics: management fees on committed capital and carried interest on realized exits. Pricing models, fee rates, and fund vintages are not disclosed in the source material. Beyond its healthcare core, Apricot Capital has extended into consumer and lifestyle investments, exemplified by a seven-figure investment in Pop Padel, a Singapore-founded padel club expanding into Malaysia. Leadership comprises founding partner Weixiong Mao, co-founding partner Liu Wenyi, managing partners Haigang Chen and Arthur Qiang, and managing director Zhen Zhang. The firm also maintains an ISO/IEC 27001:2022 certification, signaling operational information-security discipline. Note: source material contains conflicting identity signals, including references to an Armenia-domiciled 'Apricot Capital CJSC' and a separate 'post-acute care' entity reportedly backed by Insight Partners; this description prioritizes the Shanghai-headquartered healthcare-focused identity consistent with the firmographics block and the bulk of disclosed investment activity.

Short descriptiontext

Apricot Capital is a Shanghai-based venture capital firm founded in 2015 that invests in early and growth-stage healthcare and life sciences companies across Asian and Western markets, with a portfolio focused on clinical-stage biotechnology and selective consumer bets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
venture capital, healthcare investments, biotech financing, growth capital, life sciences investing
Industry1 code
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital
No data
Cost components3 values
Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Apricot Capital is a venture capital firm that invests equity capital in early-to-growing stage companies, primarily in the healthcare and life sciences sectors, with a portfolio that includes therapeutics developers such as Vibrant Therapeutics, Excalipoint Therapeutics, and Vivatides Therapeutics, plus selective non-healthcare deals such as Pop Padel. Beyond capital, the firm provides strategic guidance and network access to its portfolio companies. Founded in 2015 and headquartered in Shanghai, China, it operates with 11–50 employees.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Apricot Capital is a venture capital firm that invests in growth-stage companies across sectors including biotechnology, healthcare, and technology. Based on the source material, Apricot Capital has made investments in multiple biotech companies including Vivatides Therapeutics (RNA therapeutics), Excalipoint Therapeutics (T-cell engager therapies), Vibrant Therapeutics (oncology drug development), and Pop Padel (sports/entertainment). The firm appears to focus on providing capital and strategic support to portfolio companies rather than offering a discrete technology product or platform.

Product and service2 records
1Venture Capital Investment (Healthcare and Life Sciences Focus)
CategoryVenture Capital / Private Equity
Description

Equity capital investment in early-to-growing stage companies, with the firm's active portfolio concentrated in healthcare and life sciences (including therapeutics developers such as Vibrant Therapeutics, Excalipoint Therapeutics, and Vivatides Therapeutics). Provided to founders and boards of target portfolio companies raising growth equity.

2Growth Equity Investment Outside Healthcare
CategoryVenture Capital / Private Equity
Description

Selective growth-equity investments outside the core healthcare thesis, exemplified by the Pop Padel investment. Provided to founders and boards of non-healthcare growth-stage companies.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

China-headquartered venture firm with a dedicated healthcare/biotech franchise that has co-invested alongside Apricot in Vivatides Therapeutics. Direct overlap in Asia life-sciences investing and syndicate relationship make it the closest comparable peer.

TypeDirect peer
Description

Shanghai-based growth and venture investor with healthcare exposure, named as a recurring Apricot co-investor. Comparable cross-border China-focused fund with overlapping portfolio company base.

TypeDirect peer
Description

Healthcare-focused venture and growth investor active in China and the US; participated alongside Apricot in Vivatides' Series A. Directly comparable by therapeutic focus and stage.

TypeDirect peer
Description

China-based biotech-focused investor that co-invested with Apricot in Vivatides Therapeutics. Comparable in size, sector focus, and Chinese life-sciences mandate.

TypeDirect peer
Description

Chinese early-stage biotech investor that co-led Excalipoint Therapeutics' seed with Apricot. Closely comparable by stage, modality focus (T-cell engagers), and geography.

TypeBroad incumbent
Description

Large multi-stage China investor with a healthcare practice; co-led Excalipoint with Apricot. Larger and more diversified, but a meaningful comparator for institutional-grade China healthcare deployment.

TypeDirect peer
Description

Global healthcare-dedicated investment firm covering venture through public markets. Comparable in therapeutic specialization, cross-border footprint, and life-sciences mandate.

TypeDirect peer
Description

US-based biotech-focused venture firm investing across modalities including T-cell engagers and RNA therapeutics. Comparable in stage and therapeutic focus; benchmark for what a scaled specialist VC in Apricot's niche can become.

TypeOthers
Description

Corporate venture arm of Pfizer investing in early-stage biotech; co-invested with Apricot in Vibrant Therapeutics. Functions as a strategic capital partner and syndicate reference point rather than a direct competitor for ownership.

TypeBroad incumbent
Description

Global life-sciences investment platform with venture, growth, and public strategies. Comparable cross-border biotech thesis, but materially larger AUM and broader mandate.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment50 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Apricot Capital

Venture Capitalapricot-capital.com

Apricot Capital is a Shanghai-based venture capital firm founded in 2015 that invests in early and growth-stage healthcare and life sciences companies across Asian and Western markets, with a portfolio focused on clinical-stage biotechnology and selective consumer bets.

What Apricot Capital does

Apricot Capital is a Shanghai-based venture capital investment firm founded in 2015 that focuses on early and growth-stage companies in the healthcare and life sciences sectors. The firm operates with a team of 11-50 employees and pursues a cross-border investment strategy, co-investing alongside prominent institutional investors including Pfizer Ventures, Qiming Venture Partners, HSG, Yuanbio Venture Capital, Highlight Capital, TF Capital, and Loyal Valley Capital. Its portfolio is anchored by clinical-stage and early-clinical biotechnology companies developing T-cell engager therapies and RNA-targeting therapeutics, including Vibrant Therapeutics (T-cell engagers for solid tumors, $100M total raised), Excalipoint Therapeutics (T-cell engagers for cancer and autoimmune diseases, $68.7M seed), and Vivatides Therapeutics (extrahepatic RNA-targeting therapeutics, $54M Series A).

The firm's business model is capital deployment into portfolio companies rather than product sales, with revenue derived from conventional VC mechanics: management fees on committed capital and carried interest on realized exits. Pricing models, fee rates, and fund vintages are not disclosed in the source material. Beyond its healthcare core, Apricot Capital has extended into consumer and lifestyle investments, exemplified by a seven-figure investment in Pop Padel, a Singapore-founded padel club expanding into Malaysia. Leadership comprises founding partner Weixiong Mao, co-founding partner Liu Wenyi, managing partners Haigang Chen and Arthur Qiang, and managing director Zhen Zhang. The firm also maintains an ISO/IEC 27001:2022 certification, signaling operational information-security discipline. Note: source material contains conflicting identity signals, including references to an Armenia-domiciled 'Apricot Capital CJSC' and a separate 'post-acute care' entity reportedly backed by Insight Partners; this description prioritizes the Shanghai-headquartered healthcare-focused identity consistent with the firmographics block and the bulk of disclosed investment activity.

Apricot Capital firmographics

Firmographics
Name
Apricot Capital
Legal name
Apricot Capital CJSC
Website
https://apricot-capital.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Apricot Capital is a Shanghai-based venture capital firm founded in 2015 that invests in early and growth-stage healthcare and life sciences companies across Asian and Western markets, with a portfolio focused on clinical-stage biotechnology and selective consumer bets.
Ownership category
akta.pro rank

Apricot Capital industry classification

Industry
Product category
Venture Capital
NAICS
Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Venture capital
  • Healthcare investments
  • Biotech financing
  • Growth capital
  • Life sciences investing

Where Apricot Capital is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Markets served

Apricot Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales

Apricot Capital product offering

Product offering

Core offering

Apricot Capital is a venture capital firm that invests equity capital in early-to-growing stage companies, primarily in the healthcare and life sciences sectors, with a portfolio that includes therapeutics developers such as Vibrant Therapeutics, Excalipoint Therapeutics, and Vivatides Therapeutics, plus selective non-healthcare deals such as Pop Padel. Beyond capital, the firm provides strategic guidance and network access to its portfolio companies. Founded in 2015 and headquartered in Shanghai, China, it operates with 11–50 employees.

Product overview

Apricot Capital is a venture capital firm that invests in growth-stage companies across sectors including biotechnology, healthcare, and technology. Based on the source material, Apricot Capital has made investments in multiple biotech companies including Vivatides Therapeutics (RNA therapeutics), Excalipoint Therapeutics (T-cell engager therapies), Vibrant Therapeutics (oncology drug development), and Pop Padel (sports/entertainment). The firm appears to focus on providing capital and strategic support to portfolio companies rather than offering a discrete technology product or platform.

Differentiator

Problem solved

Functional benefit

Products and services

  • Venture Capital Investment (Healthcare and Life Sciences Focus) Equity capital investment in early-to-growing stage companies, with the firm's active portfolio concentrated in healthcare and life sciences (including therapeutics developers such as Vibrant Therapeutics, Excalipoint Therapeutics, and Vivatides Therapeutics). Provided to founders and boards of target portfolio companies raising growth equity.
  • Growth Equity Investment Outside Healthcare Selective growth-equity investments outside the core healthcare thesis, exemplified by the Pop Padel investment. Provided to founders and boards of non-healthcare growth-stage companies.

Companies that use Apricot Capital

Customer profile

Segments1 record

Ideal customer profiles1 record

Apricot Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Apricot Capital partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Apricot Capital competitors and assessment

Company assessment

Direct peers

  • Qiming Venture Partners: China-headquartered venture firm with a dedicated healthcare/biotech franchise that has co-invested alongside Apricot in Vivatides Therapeutics. Direct overlap in Asia life-sciences investing and syndicate relationship make it the closest comparable peer.
  • Loyal Valley Capital: Shanghai-based growth and venture investor with healthcare exposure, named as a recurring Apricot co-investor. Comparable cross-border China-focused fund with overlapping portfolio company base.
  • Highlight Capital: Healthcare-focused venture and growth investor active in China and the US; participated alongside Apricot in Vivatides' Series A. Directly comparable by therapeutic focus and stage.
  • TF Capital: China-based biotech-focused investor that co-invested with Apricot in Vivatides Therapeutics. Comparable in size, sector focus, and Chinese life-sciences mandate.
  • Yuanbio Venture Capital: Chinese early-stage biotech investor that co-led Excalipoint Therapeutics' seed with Apricot. Closely comparable by stage, modality focus (T-cell engagers), and geography.
  • OrbiMed: Global healthcare-dedicated investment firm covering venture through public markets. Comparable in therapeutic specialization, cross-border footprint, and life-sciences mandate.
  • ARCH Venture Partners: US-based biotech-focused venture firm investing across modalities including T-cell engagers and RNA therapeutics. Comparable in stage and therapeutic focus; benchmark for what a scaled specialist VC in Apricot's niche can become.

Broad incumbents

  • HSG (formerly Sequoia China): Large multi-stage China investor with a healthcare practice; co-led Excalipoint with Apricot. Larger and more diversified, but a meaningful comparator for institutional-grade China healthcare deployment.
  • Bain Capital Life Sciences: Global life-sciences investment platform with venture, growth, and public strategies. Comparable cross-border biotech thesis, but materially larger AUM and broader mandate.

Others

  • Pfizer Ventures: Corporate venture arm of Pfizer investing in early-stage biotech; co-invested with Apricot in Vibrant Therapeutics. Functions as a strategic capital partner and syndicate reference point rather than a direct competitor for ownership.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

Apricot Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Apricot Capital leadership team

Management profile

Number of profiles

Profiles6 records

Apricot Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Apricot Capital M&A and investment

M&A and investment

M&A

Investments50 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apricot Capital

What does Apricot Capital do?

Apricot Capital is a venture capital firm that invests equity capital in early-to-growing stage companies, primarily in the healthcare and life sciences sectors, with a portfolio that includes therapeutics developers such as Vibrant Therapeutics, Excalipoint Therapeutics, and Vivatides Therapeutics, plus selective non-healthcare deals such as Pop Padel. Beyond capital, the firm provides strategic guidance and network access to its portfolio companies. Founded in 2015 and headquartered in Shanghai, China, it operates with 11–50 employees.

Is Apricot Capital a public or private company?

Apricot Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Apricot Capital founded?

Apricot Capital was founded in 2015. It employs 1 to 10 people.

Where is Apricot Capital based?

Apricot Capital is headquartered in San Francisco, United States, in the North America region.

Who are Apricot Capital's main competitors?

Direct peers on record are Qiming Venture Partners, Loyal Valley Capital, Highlight Capital, TF Capital, Yuanbio Venture Capital, OrbiMed and ARCH Venture Partners. Broad incumbents are HSG (formerly Sequoia China) and Bain Capital Life Sciences. Pfizer Ventures is listed as an others.

Does Apricot Capital have an API?

No public API is recorded for Apricot Capital.

What industry is Apricot Capital in?

Apricot Capital's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YicaiglobalChina's iRegene Raises USD31 Million to Advance Parkinson’s and MSA Cell Therapy ProgramsiRegene Therapeutics raised CNY210 million (USD31 million) in a C1 round co-led by Luminous Ventures and Apricot Capital. The funds will advance its Parkinson's and MSA cell therapy programs, including Phase II trials for NouvNeu001 and approvals for NouvNeu004. The company aims to become an AI-driven biotechnology platform.Fastdata极数“睿健医药”完成2.1亿元C1轮融资 – Fastdata极数Ruijian Pharmaceutical completed a 210 million RMB Series C1 financing round led by Guanghe Venture Capital and Xingze Capital. The funds will advance its core clinical pipeline, upgrade its AI + chemical induction platform, build a large-scale production system, and support global clinical development and international business cooperation.VentureburnVivatides Therapeutics Raises $54M for RNA ExpansionVivatides Therapeutics raised $54 million in an oversubscribed Series A round led by Qiming Venture Partners. The funding will develop its extrahepatic RNA delivery platform, aiming to treat diseases beyond the liver. The company plans to accelerate its pipeline toward clinical validation.FinSMEsVivatides Therapeutics Raises $54M in Series A FundingVivatides Therapeutics raised $54M in Series A funding co-led by Qiming Venture Partners. The company will use the funds to advance preclinical optimization, IND-enabling studies, and expand its R&D and management teams. It aims to develop RNA therapeutics for chronic metabolic, cardiovascular, and oncology conditions.YahooExcalipoint debuts with $68.7m to progress TCE pipelineChinese biotech Excalipoint Therapeutics has emerged with $68.7 million in seed funding to advance its pipeline of T-cell engager (TCE) therapies for immunology and oncology indications. The financing was structured as a $41 million oversubscribed seed round co-led by Apricot Capital, HSG, and Yuanbio Venture Capital, followed by a $27.7 million extension round backed by Lilly Asia Ventures and Eisai Innovation. The company plans to progress six TCE programs including its lead clinical-stage trispecific antibody EXP011, currently in a Phase I/II trial for non-small cell lung cancer and neuroendocrine tumours, and will focus on cross-border partnerships and out-licensing strategies for continued growth.PMLiVEVibrant Therapeutics raises $61m in funding to advance intelligent therapeutics pipelineVibrant Therapeutics raised $61 million in new financing from Pfizer Ventures and Apricot Capital, bringing its total capital raised to $100 million, to advance its pipeline of intelligent therapeutics and develop a proprietary drug design platform. The clinical-stage biotechnology company also announced that its Investigational New Drug application for lead programme VIB305 was accepted by the US FDA, enabling the initiation of US clinical trials for the masked T-cell engager prodrug targeting EGFR-expressing solid tumours. Phase 1 trials for VIB305 are already underway in Australia and China.FinSMEsVibrant Therapeutics Raises $61M in FundingVibrant Therapeutics, a clinical-stage biotechnology company headquartered in Guangzhou, China and Cambridge, Massachusetts, has raised $61 million in new financing from investors including Pfizer Ventures and Apricot Capital, bringing its total capital raised to $100 million. The company plans to use the proceeds to advance its therapeutic pipeline, develop its proprietary drug design platform, and expand its team to support global development activities. The announcement also included the appointment of Han Lee as co-CEO and FDA acceptance of the Investigational New Drug application for its lead program VIB305 for EGFR-positive solid tumors.Pulse 2.0Qi Biodesign: Genome Editing Company Completes $75 Million In Total FundingQi Biodesign completed its Series A funding round, raising a total of $75 million across Seed, Series Pre-A, and Series A stages. The Beijing Medical and Health Care Industry Investment Fund led the round, with additional investors including CD Capital and Apricot Capital. The company will use the funds to advance its SEEDIT platform and product development.FinSMEsAmbrx Closes $45M Financing RoundAmbrx, a San Diego biopharmaceutical company, closed a $45M financing round led by Apricot Capital and Northeast Securities Prosperity Healthcare Fund. The company will use the proceeds to advance its Phase I clinical asset ARX788 and its CD3-Folate immuno-oncology program.